Akari Therapeutics (Nasdaq:AKTX) - Hisse Senedi Fiyatı, Haberler ve Analizler

AKTX Stoklara Genel Bakış

Klinik aşamada bir biyofarmasötik şirketi olan Akari Therapeutics, Plc, otoimmün ve enflamatuar hastalıklar için ileri tedaviler geliştirmeye odaklanmaktadır.

Şirket hakkında

AKTX temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Ödüller

Risk Analizi

Negatif hissedar öz sermayesi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Geliri 1 milyon ABD dolarından az ( $0 )

1 yıldan az nakit akışı var

+ 2 daha fazla risk

Akari Therapeutics, Plc Rakipler

ImmuCell

NasdaqCM:ICCC

US$28.4m

Burning Rock Biotech

NasdaqGM:BNR

US$28.9m

Tempest Therapeutics

NasdaqCM:TPST

US$27.5m

Acurx Pharmaceuticals

NasdaqCM:ACXP

US$29.9m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Akari Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$2.36
52 Haftanın En Yüksek Seviyesi	US$4.40
52 Haftanın En Düşük Seviyesi	US$1.08
Beta	0.94
11 Aylık Değişim	-19.57%
3 Aylık Değişim	-35.40%
1 Yıllık Değişim	-36.09%
33 Yıllık Değişim	-92.83%
5 Yıllık Değişim	-93.68%
Halka arzdan bu yana değişim	-99.52%

Son Haberler & Güncellemeler

Recent updates

Akari Therapeutics GAAP EPS of $0.00

Sep 27

Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?

Sep 20

Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment

Jul 28

Akari Therapeutics GAAP EPS of $0.00

Jul 20

Patient completes course with Akari's stem cell transplant related complication treatment

Jul 07

We're Keeping An Eye On Akari Therapeutics' (NASDAQ:AKTX) Cash Burn Rate

Dec 31

Akari shares rise after FDA 'fast track' status for skin disease treatment nomacopan

Apr 28

Akari Therapeutics reports FY results

Apr 21

We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully

Mar 15

Akari Therapeutics' lead candidate shows encouraging preclinical action against inflammatory eye disease

Dec 03

Hissedar Getirileri

	AKTX	US Biotechs	US Pazar
7D	9.5%	-1.3%	-0.9%
1Y	-36.1%	27.9%	38.9%

Getiri vs. Endüstri: AKTX geçen yıl % 22.1 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: AKTX geçen yıl % 34.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is AKTX's price volatile compared to industry and market?
AKTX volatility
AKTX Average Weekly Movement	10.8%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.1%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.0%

İstikrarlı Hisse Senedi Fiyatı: AKTX hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: AKTX 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	7	Samir Patel	www.akaritx.com

Klinik aşamada bir biyofarmasötik şirketi olan Akari Therapeutics, Plc, otoimmün ve enflamatuar hastalıklar için ileri tedaviler geliştirmeye odaklanmaktadır. Şirketin öncü ürün adayı, enflamatuar ve protrombotik faaliyetleri önleyen ikinci nesil bir kompleman inhibitörü olan nomacopan'dır. Şirket ayrıca kuru yaşa bağlı makula dejenerasyonuna ikincil coğrafi atrofinin tedavisi için klinik öncesi geliştirme aşamasında olan PASylated-nomacopan ve pediatrik HSCT-TMA tedavisi için faz 3 klinik geliştirme aşamasında olan nomacopan ile kombine edilmiş hematopoetik kök hücre nakli ile ilişkili trombotik mikroanjiyopati (HSCT-TMA) geliştirmektedir.

Akari Therapeutics, Plc Temel Bilgiler Özeti

Akari Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
AKTX temel i̇stati̇sti̇kler
Piyasa değeri	US$28.26m
Kazançlar(TTM)	-US$20.13m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-1.4x

F/K Oranı

AKTX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
AKTX gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$20.13m
Kazançlar	-US$20.13m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.68
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	-27.0%

AKTX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

AKTX Stoklara Genel Bakış

Ödüller

Risk Analizi

Akari Therapeutics, Plc Rakipler

NasdaqCM:ICCC

US$28.4m

NasdaqGM:BNR

US$28.9m

NasdaqCM:TPST

US$27.5m

NasdaqCM:ACXP

US$29.9m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Akari Therapeutics Receives Delisting Determination Letter from Nasdaq Due to Failure to Meet the Terms of an Extension Granted by Nasdaq to Regain Compliance with the Stockholders’ Equity Requirement

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Akari Therapeutics, Plc announced delayed 10-Q filing

New major risk - Share price stability

Akari Therapeutics, plc Appoints Samir R. Patel as Interim President

Akari Therapeutics, Plc, Annual General Meeting, Jun 27, 2024

Recent updates

Akari Therapeutics Receives Delisting Determination Letter from Nasdaq Due to Failure to Meet the Terms of an Extension Granted by Nasdaq to Regain Compliance with the Stockholders’ Equity Requirement

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Akari Therapeutics, Plc announced delayed 10-Q filing

New major risk - Share price stability

Akari Therapeutics, plc Appoints Samir R. Patel as Interim President

Akari Therapeutics, Plc, Annual General Meeting, Jun 27, 2024

Akari Therapeutics, Plc announced that it has received $0.5 million in funding

New major risk - Financial position

Melissa Bradford-Klug to Step Down as Chief Operating Officer of Akari Therapeutics, Plc

Akari Therapeutics Receives a Letter from the Listing Qualifications Staff of the Nasdaq Capital Market

New minor risk - Share price stability

New major risk - Shareholder dilution

New major risk - Market cap size

Akari Therapeutics, Plc (NasdaqCM:AKTX) entered into a definitive agreement to acquire Peak Bio, Inc. (OTCPK:PKBO).

Akari Therapeutics Appoints Samir R. Patel, M.D. to Board of Directors

Akari Therapeutics, Plc announced that it expects to receive $2 million in funding

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Akari Therapeutics, Plc Announces Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs, Effective September 1, 2023

Akari Therapeutics, plc Grants Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

Akari Therapeutics, plc Announces Appointment of Wendy Dicicco as Interim Chief Financial Officer

Less than half of directors are independent

Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

Akari Therapeutics, plc Announces Updates on the Development of Long-Acting Pas-Nomacopan as A Potential Treatment for Geographic Atrophy

Akari Therapeutics, plc Announces Management Appointments

Akari Therapeutics, Plc, Annual General Meeting, Jun 30, 2023

Akari Therapeutics, Plc Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy

Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric Hsct-Tma into Pivotal Part B and Addition of A New Pipeline Program Developing Nomacopan for Hsct-Tma in Adults

Price target decreased to US$4.00

Insufficient new directors

Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of nomacopan for the Treatment of Pediatric HSCT-TMA

Akari Therapeutics Announces the Appointment of John F. Neylan, III as Executive Vice President, Chief Medical Officer

Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Akari Therapeutics GAAP EPS of $0.00

Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?

Akari Therapeutics, plc Announces That It Is Prioritizing Two Pipeline Programs

Insufficient new directors

Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy

Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment

Akari Therapeutics GAAP EPS of $0.00

Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase Iii Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy

Patient completes course with Akari's stem cell transplant related complication treatment

Akari Therapeutics, Plc Appoints Melissa Bradford-Klug as Chief Operating Officer, Effective July 1, 2022

Akari Therapeutics, Plc, Annual General Meeting, Jun 30, 2022

Akari Therapeutics, Plc Presents Results from the CASCADE and CORONET Studies in COVID-19

Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology

Akari Therapeutics, Plc Presents Positive Results from Two Preclinical Studies of Its Lead Asset, Investigational Nomacopan

Insufficient new directors

Akari Therapeutics, Plc Appoints Rachelle Jacques as President and Join its Board of Directors

Akari Therapeutics, Plc Appoints Rachelle Jacques as President and Join its Board of Directors

Akari Therapeutics, plc Announces New Data Showing That Clinical Outcomes in U.S. Army Trauma Patients Correlate with Complement Activation

Akari Therapeutics, plc Announces Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases

Akari Therapeutics, Plc announces FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies

We're Keeping An Eye On Akari Therapeutics' (NASDAQ:AKTX) Cash Burn Rate

Akari Therapeutics, Plc Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders

Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid

Akari shares rise after FDA 'fast track' status for skin disease treatment nomacopan

Akari Therapeutics reports FY results

We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully

Akari Therapeutics, Plc Announces a Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research for Nomacopan in Trauma